|Videos|September 15, 2014

Quality Measures Within Medicare Part D for Drug Adherence

Sam Stolpe, PharmD, describes several quality measures that revolve around safe and appropriate medication use.

Sam Stolpe, PharmD, associate director of quality strategies at the Pharmacy Quality Alliance, describes several quality measures that revolve around safe and appropriate medication use, making them relevant for pharmacists.

For example, Dr. Stolpe explains, Medicare Advantage Plans (Part C) and Prescription Drug Plans (Part D) have 3 measures of medication adherence, including a metric on the appropriate treatment of hypertension in patients with diabetes.

“There’s a trend towards harmonization across measure sets, which is a really good thing, especially for pharmacy,” Dr. Stolpe notes.

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Quality Measures Within Medicare Part D for Drug Adherence

Related Content

McKesson ideaShare 2026: Project Oasis Expansion and New Diabetic Retinopathy Screening Program Explained

McKesson ideaShare 2026: How AI, Diversification, and Peer Learning Are Shaping Pharmacy Education

Oncology Pharmacists Connect 2026: Putting Data into Practice

Emerging Biomarkers and Precision Treatment Sequencing in Breast Cancer Care

Optimizing Bispecific Therapy Selection and Monitoring Across Oncology Practice Settings

Latest CME

Innovations in Hidradenitis Suppurativa Treatment: Navigating the Evolving Landscape

Beyond the Nasal Passage: Managing Chronic Rhinosinusitis With Nasal Polyps With Biologics and Pharmacist-Led Approaches

Neuropsychiatry Day of Education 2026

Outsmart the Algorithm: Combatting Misinformation at the Pharmacy Counter

Understanding mRNA Vaccines: Dispelling Myths and Empowering Pharmacists to Counsel Patients (Pharmacy Technician Credit)

Navigating the Legal Landscape of Telehealth: Updates and Implications for Pharmacists and Technicians (Pharmacy Technician Credit)

Targeting Genomic Drivers to Optimize ROS1-Directed Therapy in NSCLC

Oncology Pharmacists Connect 2026

The Educated Pharmacist: Using Patient Insights to Personalize Insulin Therapy and Prevent Clinical Inertia

Enhancing Patient Outcomes in Metastatic Colorectal Cancer: Equipping Community, Veterans Affairs, and Oncology Pharmacists to Navigate Care in the Third-Line Setting and Beyond

Adapting to Advances in EGFR-Positive Non-Small Cell Lung Cancer Treatment: Critical Insights for Oncology Pharmacists

Understanding mRNA Vaccines: Dispelling Myths and Empowering Pharmacists to Counsel Patients

Clinical Presentation of Hyperglycemia with PI3K and AKT Inhibitors

Multidisciplinary Insights and Strategies for Patients Treated With PI3K and AKT Inhibitors to Prevent Hyperglycemia

Multidisciplinary Insights to Enhance Biomarker Testing Practices in Non-Small Cell Lung Cancer

Advancing Treatment Strategies in Extensive-Stage Small Cell Lung Cancer: Enhancing Pharmacist Competence in Therapy Selection, Administration, and Adverse Event Management

Transforming Gout Care: Navigating Barriers and Therapeutic Advances in Disease Management

Addressing Gaps in Care for the Rapid and Long-Term Management of Hyperkalemia With Novel Oral Potassium Binding Agents: Insights for Managed Care Professionals

New Therapeutic Targets in the Treatment of Generalized Myasthenia Gravis: Understanding Disease Pathways and Pharmacist-Led Strategies for Optimized Care

Pharmacists at the Forefront: Enhancing Targeted Therapy Implementation and Patient Outcomes in Advanced Gastric Cancer

Managing Overactive Bladder in Older Adults: Challenges and Strategies for Long-Term Care

From Payload to Patient: Managing Toxicities of Antibody-Drug Conjugates Directed at HER2 and TROP2

Exploring Immunotherapy Strategies in Endometrial Cancer

Best Practice Approaches for Understanding Chronic Obstructive Pulmonary Disease and Precision Medicine Treatment

Collaborative Practice Agreement Implementation and Adherence: A Practical Roadmap for Oncology Pharmacists

HER2-Positive Metastatic Breast Cancer: A Managed Care Perspective on Emerging Therapies and Clinical Data

Enhancing The Role of Oncology Pharmacists in Multidisciplinary Myeloproliferative Neoplasm Care

Biomarker Testing in Practice: Navigating Modalities and Multidisciplinary Decision-Making

Advancing Patient Safety: Strategies to Address Safety Risks and Adherence Barriers to Optimize Outcomes for Patients on Injectable Therapies

VMAT2 Inhibitors for Long-Term Success in Tardive Dyskinesia

Expanding the Role of Long-Acting Injectables in Optimizing Schizophrenia Management

Bridging Knowledge Gaps in HR+/HER2– Early-Stage Breast Cancer

Shaping the Future of Generalized Myasthenia Gravis Management: A Focus on Novel Treatment Approaches

Expert Insights on the Horizon of HER2-Directed Therapy

Breaking Barriers in Asthma Care: Exploring the Role of Type 2 Inflammation and Biologic Therapies

From Flares to Freedom: Navigating the Journey of Patients With Chronic Spontaneous Urticaria With Next-Generation Therapies

Type 2 Inflammation in Focus: Advancing Pediatric Atopic Dermatitis Care With Biologic Therapies

Chronic Obstructive Pulmonary Disease and Inflammation: Practical Approaches to Integrating Biologic Therapy

Understanding Type 2 Inflammation and Its Role Across Various Immune-Related Diseases

Innovations in Lymphoma Treatment and the Growing Impact of Bispecific Antibodies

Payment for Pharmacist Services: 2025 Update

From Treatment to Prevention: Navigating the Expanding Hereditary Angioedema Treatment Landscape

The Oncology Pharmacist's Role in Managing Small Molecule Inhibitor Use in Chronic Lymphocytic Leukemia to Enhance Patient-Centered Care

Redefining Complement-Mediated Kidney Disease: The Latest in Diagnosis and Treatment

Advancing Pharmacist Expertise in R/R FL: Navigating Novel Therapies and Optimizing Patient Outcomes

Optimizing Outcomes in Myasthenia Gravis: Therapeutic Advances and Value-Based Care Models

Navigating Novel Therapies in Steroid-Refractory cGVHD: Practical Strategies for Community-Based Oncology Pharmacists

Reducing Transfusion Burden in Myeloid Disorders: Novel Therapeutic Strategies and Pharmacist Interventions

Panel Discussion: Integrating Novel Combinations and Earlier Line Use in Diffuse Large B-Cell Lymphoma

Optimizing Patient Outcomes in R/R DLBCL: Bridging Knowledge Gaps for Oncology Pharmacists in the Era of Novel Immunotherapies

The Pharmacist's Role in Palliative and End of Life Symptom Management

From Molecules to Medicine: Pharmacologic Principles of Innovative Non-Hodgkin Lymphoma Therapies

The Pharmacist's Role in Palliative and End of Life Symptom Management (Pharmacy Technician Credit)

Navigating the Legal Landscape of Telehealth: Updates and Implications for Pharmacists and Technicians

From Testing to Treatment: Empowering Pharmacists to Overcome Barriers and Optimize Biomarker-Driven Care

Reducing the Treatment Burden in HIV Management: The Pharmacist’s Role in Long-Acting Injectable Adoption

Addressing Vaccine Hesitancy in Infectious Disease Prevention

Optimizing Lipid Management in Statin-Intolerant Populations: Payer Strategies for Evidence-Based Access and Risk Reduction

IL-23 Inhibitors in Psoriasis: Optimizing Access and Patient Outcomes Across Integrated Systems

Targeting the Root of Autoimmunity in Generalized Myasthenia Gravis: Pharmacist Strategies for Integrating FcRn Therapies Into Specialty Practice

Utilizing VMAT-2 Inhibitors for the Management of Tardive Dyskinesia: The Role of Long-Term Care Pharmacists

Influenza Immunization in Older Adults: Enhanced Vaccines and Best Practices for Long-Term Care Pharmacists

Bridging Innovation and Access in HR-Positive/HER2-Negative Metastatic Breast Cancer: Implications for Managed Care

Cardiorenal Protection With SGLT2 Inhibitors: Perspectives for Managed Care

New Horizons in ATTR-CM: Therapeutic Advances and Strategic Insights

Navigating Advanced Prostate Cancer Treatment: Optimizing Novel Therapeutic Strategies for Managed Care Pharmacists

Effective Strategies to Manage Hyperglycemia When Treating with PI3K and AKT Inhibitors

Bridging Clinical and Access Gaps in Phenylketonuria: A Managed Care Perspective

Sugar, We’re Going Down: Navigating Glycemic Control in the Era of PI3K/AKT Inhibition for Breast Cancer

From Molecule to Medication: Integrating Menin Inhibitors in AML Practice

Improving Outcomes in Lipid Management: Aligning Managed Care Policy With Emerging Guideline Updates and Non-Statin Therapeutic Advances

Identifying and Personalizing Iron Deficiency Anemia Treatment in Patients With Cancer